CURRICULUM VITAE NAME - Department of Anatomy and Cell
Transcription
CURRICULUM VITAE NAME - Department of Anatomy and Cell
CURRICULUM VITAE NAME: Feng-Chun Yang, M.D., PhD ADDRESS: Indiana University School of Medicine Herman B Wells Center for Pediatric Research Cancer Research Institute 1044 W. Walnut, Bldg. R-4, Room 427 Indianapolis, IN 46202 Phone: (317) 274-4178 Fax: (317) 274-8928 Email: [email protected] EDUCATION: 1983 M.D., Hebei Medical University 1996 Ph.D. – Hematology/Oncology, Shinshu University ACADEMIC APPOINTMENTS: 1983 - 1991 Resident, Pediatric Fellow & Instructor, Central Hospital, Shijiazhuang, China 1996 - 1998 Research Fellow, Japanese Society for the Promotion of Science, The Institute of Medical Science, University of Tokyo, Japan (with Dr. T. Nakahata) 1998 - 2001 Postdoctoral Research Fellow, Howard Hughes Medical Institute 2001 - 2004 Research Associate Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana 2004 - 2005 Assistant Research Professor, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana 2005 – Present Assistant Professor, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana 2007 – Present Adjunct Assistant Professor, Department of Anatomy and Cell Biology, Indiana University School of Medicine, Indianapolis, Indiana 2006 – Present Honorary Professorship, Hebei Medical University, China PROFESSIONAL ORGANIZATIONS: 1998 - Present American Society of Hematology 1998 - Present International Society for Experimental Hematology 2009 -Present American Society for Bone and Mineral Research Selected Peer Reviewed Publications (since 2006): 1. F-C Yang, S. Chen, T. Clegg, X. Li, T. Morgan, S.A. Estwick, J. Yuan, W. Khalaf, S. Burgin, J. Travers, L.F. Parada, D.A. Ingram, and D.W. Clapp. Nf1+/- mast cells induce Feng-Chun Yang, CV, 1 neurofibroma like phenotypes through secreted TGF-b signaling. Human Molecular Genetics 16:1-17 2006 2. F-C Yang, S. Chen, A.G. Robling, X. Yu, T.D. Nebesio, J. Yan, T. Morgan, X. Li, Jin Yuan, J. Hock, D.A. Ingram and D.W. Clapp. Hyperactivation of p21ras and PI3-K cooperate to alter murine and human NF1 haploinsufficient osteoclast functions. Journal of Clinical Investigation 116:2880-2891 2006 3. X. Wu, S.A. Estwick, S. Chen, W. Ming, T.D. Nebesio, Y. Li, J. Yuan, K. Reuben, D. Ingram, M.C. Yoder, F-C Yang. Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem /progenitor cells. Human Molecular Genetics 15:28372845, 2006. 4. A.M. Munchhof, F. Li, H.A. White, L.E. Mead, T.R. Krier, A. Fenoglio, X. Li, J. Yuan, F-C Yang and D.A. Ingram. Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells. Human Molecular Genetics 15:1858-1869, 2006 5. F. Li, A.M. Munchhof, H.A. White, L.E. Mead, T.R. Krier, A. Fenoglio, S. Chen, X. Wu, S. Cai, F-C Yang and D.A. Ingram. Neurofibromin is a novel regulator of RAS-induced signals in primary vascular smooth muscle cells. Human Molecular Genetics 15:1921-1930, 2006 6. L.S. Haneline, H. White, F-C Yang, S. Chen, C. Orschell, R. Kapur, and D.A. Ingram. Genetic reduction of class IA PI-3 kinase activity alters fetal hematopoiesis and competitive repopulating ability of hematopoietic stem cells in vivo. Blood 107:1375-1382, 2006 7. Si Y, Ciccone S, F-C Yang, Yuan J, Zeng D, Chen S, van de Vrugt H, Critser J, Arwert F, Haneline LS, Clapp DW. Related Articles, Links Continuous in vivo infusion of interferongamma (IFN-{gamma}) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice. Blood. 108:4283-4287, 2006 8. Nebesio TD, Ming W, Chen S, Clegg T, Yuan J, Yang Y, Estwick SA, Li Y, Li X, Hingtgen CM, F-C Yang. Neurofibromin-deficient Schwann cells have increased lysophosphatidic acid dependent survival and migration-implications for increased neurofibroma formation during pregnancy. Glia. 55:527-536. 2007 9. Khalaf WF, F-C Yang, Chen S, White H, Bessler W, Ingram DA, Clapp DW. K-ras Is Critical for Modulating Multiple c-kit-Mediated Cellular Functions in Wild-Type and Nf1+/Mast Cells. J Immunol. 178:2527-2734, 2007 10. B. Li, N. Jia, D.L. Waning, F-C Yang, L.S. Haneline, K.T. Chun. Cul4A is required for hematopoietic stem cell engraftment and self-renewal. Blood 2007 11. J. Yan, S. Chen, Y. Zhang, Y. Li, X. Li, J. Yuan, S. Estwick, A. Robling, R. Kapur, R.J. Chan, F-C Yang. Rac1, but not Rac2, mediates osteoclast gain-of-function induced by Nf1 haploinsufficiency. Hum Mol Genet, 2008 12. Goodman ML, Chen S, F-C Yang, Chan RJ. Novel Method of Murine Embryonic Stem CellDerived Osteoclast Development. Stem Cells Dev. 2008 13. Perry BC, Zhou D, Wu X, Yang F-C, Byers MA, Chu TM, Hockema JJ, Woods EJ, Goebel WS. Collection, cryopreservation, and characterization of human dental pulp-derived mesenchymal stem cells for banking and clinical use. Tissue Eng Part C Methods. 2008 Jun;14(2):149-56 14. Pulliam AC, Hobson MJ, Ciccone SL, Li Y, Chen S, Srour EF, Yang FC, Broxmeyer HE, Clapp DW. AMD3100 synergizes with G-CSF to mobilize repopulating stem cells in Fanconi anemia knockout mice. Exp Hematol. 2008 Sep;36(9):1084-90 15. F-C Yang, D.A. Ingram, S. Chen, Y. Zhu, J. Yuan, X. Li, X. Yang, S. Knowles, W. Horn, Y. Li, S. Zhang, S.T. Vakili, M. Yu, D. Burns, K. Robertson, G. Hutchins, L.F. Parada, D.W. Feng-Chun Yang, CV, 2 Clapp. NF1 tumor suppressor haploinsufficient bone marrow complements nullizygous Schwann cells to form plexiform neurofibromas. CELL 135:437-448, 2008 16. Munugalavadla V, Vemula S, Krishnan S, Sims EC, Chen S, Yan J, Li H, Niziolek PJ, Takemoto C, Robling AG, Yang FC, Kapur R. p85{alpha} subunit of class IA PI-3Kinase regulates the expression of multiple genes involved in osteoclast maturation and migration. Cell Biol. 28:7182-7198, 2008 17. Li Y, Chen S, Yuan J, Yang Y, Li J, Ma J, Wu X, Freund M, Pollok K, Hanenberg H, Goebel WS, Yang FC. Mesenchymal stem/progenitor cells promote the reconstitution of exogenous hematopoietic stem cells in Fancg-/- mice in vivo. Blood 2009 Mar 5;113(10):2342-51. Epub 2009 Jan 7 18. H. Li, Y. Liu, Q. Zhang, Y. Jing1, S. Chen, Z. Song, J. Yan, Y. Li, X. Wu, X. Zhang, Y. Zhang, J. Case, M. Yu, DA. Ingram, F-C Yang. Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model. Pediatric Res. 2009 Jun;65(6):613-8. 19. Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, Schorry EK, Crawford AH, Friedman JM, Little D, Peltonen J, Carey JC, Feldman D, Yu X, Armstrong L, Birch P, Kendler DL, Mundlos S, Yang F-C, Agiostratidou G, Hunter-Schaedle K, Stevenson DA.Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A. 2009 149A(10):2327-38 20. Benson EA, Goebl MG, Yang F-C, Kapur R, McClintick J, Sanghani S, Clapp D and Harrington M. Loss of SIMPL Compromises TNFα Dependent Survival of Hematopoietic Progenitors. Exp Hemato 2009 (in press) 21. H. Hirasawa, C. Jiang, P. Zhang, Yang F-C, H. Yokota. Mechanical stimulation suppresses phosphorylation of eIF2a and PERK-mediated responses to stress to the endoplasmic reticulum. FEBS Letters 2010, 584: 745–752 22. Staser K, Yang FC, Clapp DW. Mast cells and the neurofibroma microenvironment. Blood. 2010 March 16. 23. Nebesio T., Chen S., Yang FC. What accounts for the variable responses to progesterone on Schwann cells from mice and humans – the species-specific influence or the paracrine effects from the tumor microenvironment? Cancer Biology & Therapy 10:11, 1-2 2010 24. Chen S., Burgin S., McDaniel A, Li X., Yuan J, Chen M, Khalaf W, Clapp DW, and Yang FC. Nf1-/- Schwann cell conditioned medium modulates mast cell degranulation by C-Kit mediated hyperactivation of PI-3 kinase. American Journal of Pathology 2010 (accepted). Grant source ACTIVE NF073112 02/01/08-02/28/11 Department of Defense (PI-Yang) $174,993/year Identification of the cellular and molecular mechanisms underlying the osseous manifestations of NF1 in murine and human systems Goals: To generate a murine model that recapitulates the scoliosis and osteoporosis manifestations prevalent in NF1 patients, and to identify the role of Ras/Erk signaling axis on murine and human OBL progenitors development. Feng-Chun Yang, CV, 3 06/01/08-05/31/11 March of Dimes Birth Defects Foundation (PI-Yang) $78,373/year Genetic, Functional, and Biochemical Characterization of Neurofibromin Dependent Skeletal Dysplasias Utilizing Murine Models The goal of this application is to test the hypothesis that nullizygous loss of Nf1 in preosteoblasts/osteoblasts and haploinsufficiency of Nf1 in other lineages (Nf1+/-;ob-/-) are collectively necessary and sufficient to induce pathological changes in skeletal biomechanics and signaling pathways mediating the pathogenesis. R01 CA074177-13 (PI-Clapp, Yang-co-PI) 05/01/08-02/28/13 NIH $223,789/year Neurofibromatosis Type 1 Gene Regulates Myelopoiesis This grant examines the effect of genetic inactivation of RAC proteins on neurofibromin deficient myeloid cells. Role: Co-Investigator 08/01/08-07/31/11 Doris Duke Research Foundation (PI-Stevenson, Co-PI-Yang) $22,784/year Effects of Germline Mutations within the Ras Pathway on Bone Remodeling The goal of this study is to determine how PTPN11 and NF1 mutations affect osteoclast function and bone abnormalities in individuals with Noonan syndrome and Neurofibromatosis type 1, respectively. Role: Co-Investigator U01 NS055849-02 (PI-Clapp, Yang, co-PI) 07/01/08-06/30/12 NIH-NINDS $415,563/year Preclinical Testing of Targeted Therapies for Neurofibromas Goals: Evaluation of experimental compounds in a preclinical model of plexiform neurofibromas Role: Co-Investigator, Group Leader for Team 2 W81XWH-09-1-0120 (PI-Robertson, Yang Co-I) 04/01/09-03/31/12 DOD $250,000/year Pilot Study Of Gleevec®/Imatinib Mesylate (STI-571, NSC 716051) In Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas The major goal of this project is to test the use of known therapeutic agents on a novel use i.e., shrinkage of tumors in patients with neurofibromatosis. We will also pilot a NF-specific health related quality of life tool. Role: Co-Investigator P50 NS 052606-04 (PI-Parada, Yang-Multi-PI project 2) 07/01/10 – 06/30/15 NIH/NINDS/UTSW $211,525/year Role of hematopoietic microenvironment in plexiform neurofibroma progression Goals: Evaluate the role of monocyte/ macrophages in plexiform neurofibroma formation R01 (Yang-Multi-PI with Drs. Clapp & Hanenberg) 12/01/2010-11/30/2015 NIH $250,000/year Genetic Therapy for Fanconi Anemia Feng-Chun Yang, CV, 4 PENDING: W81XWH-10-NFRP-IIFRA (Yang) 09/30/11-09/29/14 DOD $223,204 Identifying molecular and pharmacologic targets for impaired healing in a murine model of NF1 Goals: The studies proposed here will allow us to further test potential therapeutics for the treatment of non-union fracture healing using both genetic murine models and pharmacologic inhibitors. By completing our studies, we will be able to answer whether genetic or pharmacologic targeting of our hypothesized pathway improves fracture healing in a murine model of NF1. DOD (PI-Yang) 12/01/10-11/30/13 $250,000/annual Title: Identifying molecular and pharmacologic targets for impaired fracture healing in murine model of NF1. RO1 (PI-Yang) 07/01/11-06/30/16 $250,000/annual Title: Neurofibromin controls fracture healing Previous Support: Investigating the functional role of microenvironment in supporting hematopoiesis utilizing Fancg-/- murine model. Simmons grant. $25,000 PI - FC Yang Evaluation of the Role of Haploinsufficiency of NF1 in Modulating Osteoclast Cell Fates and Skeletal Formation. Research Support Funds Grant (RSFG) $30,000 PI – FC Yang Identification of the biochemical mechanisms underlying the pathological increase in de novo cytokine production in murine Nf1+/- mast cells and human NF1 mast cells. Department of Defense (W81XWH-05-1-0161, NF043032), Annual Direct Costs $150,000.00/yr. PI – FC Yang From Animal Models To Therapeutics, University of Texas Southwestern, P50 NS052606, Project 3, 7/1/05 – 6/30/10, Annual Direct Costs, $378,750. PI DW Clapp. Co-PI – FC Yang Feng-Chun Yang, CV, 5